中国癌症杂志 ›› 2021, Vol. 31 ›› Issue (7): 651-688.doi: 10.19401/j.cnki.1007-3639.2021.07.013

• 指南与共识 • 上一篇    

肿瘤相关性高血糖管理指南(2021年版)

中国抗癌协会肿瘤内分泌专业委员会,重庆市中西医结合学会肿瘤内分泌分会   

  • 出版日期:2021-07-30 发布日期:2021-08-04
  • 通信作者: 周 琦 E-mail: qizhou9128@163.com
  • 基金资助:
    国家科技部重大专项(2016YFC1303702);重庆市科技局与卫健委联合中医药技术创新与应用发展资助项目(2020ZY013540);重庆市科技局与卫健委联合技术创新与应用发展项目面上项目(2021MSXM311);重庆市沙坪坝区决策咨询与管理创新项目(Jcd202038)。

Guidelines for the management of tumor-associated hyperglycemia (2021 edition)

Onco-endocrinology Society of Chinese Anti-Cancer Association, Onco-endocrinology Committee of Chongqing Association of Integrative Medicine#br#   

  • Published:2021-07-30 Online:2021-08-04
  • Contact: ZHOU Qi E-mail: qizhou9128@163.com

摘要: 恶性肿瘤逐渐成为中国最常见的威胁生命的慢性非传染性疾病,近年来研究发现,恶性肿瘤与高血糖及糖尿病关系密切。一方面,高血糖和糖尿病可以增加多种恶性肿瘤的发病率,且与其不良预后密切相关。另一方面,部分肿瘤本身可导致高血糖和糖尿病。此外,在治疗恶性肿瘤的过程中也会出现高血糖和糖尿病。以上统称为肿瘤相关性高血糖,但目前尚无相关的指南可用于指导临床诊治和管理。中国抗癌协会肿瘤内分泌专业委员会和重庆市中西医结合学会肿瘤内分泌分会组织专家对肿瘤相关性高血糖的研究进展进行归纳总结,旨在及时传递重要信息,指导临床实践。本指南主要涵盖肿瘤相关性高血糖的概述、临床诊治管理和长期随访管理,将有助于临床医师对肿瘤相关性高血糖患者进行规范化管理,改善中国肿瘤相关性高血糖患者的临床结局。

关键词: 肿瘤相关性高血糖, 管理, 指南

Abstract: Malignant tumors have gradually become the most common chronic non-communicable diseases in China. Recent research has indicated that malignant tumors are closely associated with hyperglycemia and diabetes. On one hand, hyperglycemia and diabetes increased the morbidity of many malignant tumors, and are related to their poor prognosis. On the other hand, some tumors can also cause hyperglycemia and diabetes. In addition, hyperglycemia and diabetes may occur during the treatment of malignant tumor. These are all described as tumor-associated hyperglycemia. However there is no relevant guidance for clinical diagnosis, treatment and management. Experts from the Onco-endocrinology Society of Chinese Anti-Cancer Association and Onco- endocrinology Society of ChongQing Integrative Medicine Association summarized the research progress of tumor-associated hyperglycemia, aimed to transmit recent important progress and guide clinical practice. This guideline mainly covered the overview of tumor-associated hyperglycemia, clinical diagnosis, treatment and long-term follow-up management. This guideline may help clinicians to standardize the management of patients with tumor-associated hyperglycemia, and improve the clinical outcomes of patients with tumor-associated hyperglycemia in China.

Key words:  Tumor-associated hyperglycemia, Management, Guidelines